Drugs / SEL-212
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02648269 | Dec 2015 → Dec 2016 | gout | Selecta Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEL-212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02648269 ↗ |
| Route | Intravenous | “a single intravenous dose of SEL-212, SEL-037 (pegsiticase) plus SEL-110” NCT02648269 ↗ |